newsfilter
← Latest News
Business Wire·

Deciphera Pharmaceuticals Announces Nature Medicine Publication of Results from Exploratory ctDNA Analysis from INTRIGUE Phase 3 Study Demonstrating Substantial Clinical Benefit of QINLOCK® in 2L GIST Patients with Mutations in KIT Exon 11 and 17/18

– Median Progression-Free Survival for QINLOCK® of 14.2 Months Versus 1.5 Months for Sunitinib – – Objective Response Rate of 44.4% for QINLOCK Versus 0% for Sunitinib – – Median Overall Survival for QINLOCK